Utah Clinical Trials

A listing of Utah clinical trials actively recruiting patient volunteers.

Settled predominantly by Mormons in the 1800s, Utah stands out for the lowest income inequality of any U.S. state. Its capital and largest city is Salt Lake City, which serves as the world headquarters of the LDS Church. Other key cities are Park City, St. George, and Ogden. Utah's unique history gives it a flavor unlike anywhere else in the United States. Healthcare is a high priority. Intermountain Regional Medical Center, flagship of Intermountain Healthcare, sees patients from Utah, Idaho, Wyoming, and Nevada. It has more than 500 beds and is the largest hospital in Utah, near Salt Lake City.

Search by Name
Search
Filter by Condition
1247 trials found

RiLuzole to Reduce Atrial FIbrillatiON A Prospective, Double-Blind, Randomized, Placebo-Controlled Study Using Holter Monitoring

NCT05292209

Atrial fibrillation (AF) is a growing clinical problem.1 AF is a highly dynamic condition involving episodes of sinus rhythm interspersed with periods of arrhythmia, becoming more difficult to terminate over time. AF carries a substantial cost, morbidity and mortality burden. There are two important approaches to the management of AF: 1). Controlling ventricular response rate without attempting to terminate or prevent AF (rate control), and 2). Attempting to control and maintain sinus rhythm (rh ...

Conditions: Atrial Fibrillation Paroxysmal

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT05295927

The purpose of this study is to determine safety, including dose limiting toxicities, and the recommended phase 2 dose (RP2D) of EPI-7386 in separate combinations with (a) abiraterone acetate plus prednisone or prednisolone (AAP) and (b) apalutamide (dose-finding) and to determine the antitumor activity of EPI-7386 in separate combinations with (a) AAP and (b) apalutamide (dose-expansion).

Conditions: Prostatic Neoplasms

Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort

NCT05295277

The purpose of this research use only (RUO) study is to detect genomic structural variants (SVs) in human DNA by Optical Genome Mapping (OGM) using the Bionano Genomics Saphyr system. SVs are a type of genetic alternation that includes deletions, duplications, and both balanced and unbalanced rearrangements (ex: inversions or translocations), as well as specific repeat expansions and contractions. The results of OGM analysis will be compared to prior clinical genetic test results to determine ho ...

Conditions: Developmental Disability, Intellectual Disability, Autism Spectrum Disorder, Congenital Anomaly, Fragile X Syndrome, Facioscapulohumeral Muscular Dystrophy 1

Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

NCT05297812

Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. The purpose of this study is to examine the density of the lung as measured by chest computed tomography (CT) and determine if existing emphysema predicts changes in the rate of subsequent emphysema or changes in CT, serum or plasma biomarkers of interest. The overarching goal is to develop biomarkers that can be used in interventional trials since lung function changes do not typically inform ...

Conditions: Alpha 1-Antitrypsin Deficiency, Genetic Disease

NA-AION Risk Factors: New Perspectives

NCT05305079

The purpose of the study is to use new diagnostic methods (OCT and OCT-A) to shed light on risk factors for the development of NA-AION. The risk factors we are focusing on are comorbidities along with anatomical and vascular characteristics of the optic nerve.

Conditions: Non-arteritic Ischemic Optic Neuropathy, Optic Disk Drusen

A Study of Seltorexant in Participants With Probable Alzheimer's Disease

NCT05307692

The purpose of this study is to investigate the effect of seltorexant versus placebo on the sum of Agitation and Aggression domain scores (A plus A) of the Neuropsychiatric Inventory-Clinician rating (NPI-C) in participants with probable Alzheimer's Disease (AD) with clinically significant agitation/aggression.

Conditions: Alzheimer Disease

Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery

NCT05315479

This study is an open-label, multicenter evaluation of Safety and Pharmacokinetics of N1539 in postoperative Pediatric subjects aged 2 to <17 years.

Conditions: Post Operative Pain

A Randomized Phase III Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT05316701

This study will compare the safety and efficacy between patients receiving an engineered donor graft ("Orca-T", a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells) or standard-of-care (SOC) control in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation (MA-alloHCT) for hematologic malignancies. This posting represents the Phase III component of Precision-T. The Precision-T Ph1b component is described under NC ...

Conditions: Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, High-risk Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome

Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.

NCT05317312

MR-107A-02 is being studied to investigate its efficacy, safety and dose-response after dental surgery.

Conditions: Acute Pain, Post Operative Pain, Pain

Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

NCT05323734

This is a Phase 3, global, double-blind, randomized, placebo-controlled study of adjunctive GNX treatment in children and adults with TSC-related epilepsy. The study consists of a 4-week prospective baseline phase, defined as the first 28 days following screening, followed by a double-blind phase consisting of a 4-week titration period (with 2 additional weeks allowed, if necessary, for tolerance) and a 12-week maintenance period.

Conditions: Tuberous Sclerosis

The Effects of an Oral Probiotic Intervention With or Without a Novel ADP-1 Toothpaste

NCT05330793

Randomized double-blind, placebo-controlled trial on the effects of an oral probiotic intervention with or without a novel ADP-1 toothpaste Objective Determine the safety and effectiveness of oral probiotic intervention with or without a novel toothpaste and compare with placebo

Conditions: Oral Health
Phase: Not Applicable

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

NCT05333289

The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1020, mRNA-1030, and mRNA-1010 vaccines against vaccine-matched influenza A and B strains.

Conditions: Seasonal Influenza
Phase: Phase 1/2